Company
The Great Pioneer for Incurable Diseases

LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.”

Leadership
Team
  • CEO
    Hwasup Chin
    Bio Industry 20+ yrs
  • COO
    Jaeseok Shim, Ph.D.
    Material development,
    Industrialization 20+ yrs
  • CFO
    Junyoung Kil, CPA
    Investment 12+ yrs
  • CTO
    Seongwoon Roh, Ph.D.
    Microbiome research 20+ yrs
  • CTO
    Kyoungsub Song, Ph.D.
    Metabolism research 14+ yrs
  • Sr. Director
    Claire Kim
    Clinical development 15+ yrs
Scientific Advisory Board
  • SAB
    Theresa LaVallee, Ph.D.
    Pre-clinical, clinical 25+ yrs
  • SAB
    Robert R. Jenq, M.D.
    Cancer immunology 20+ yrs
  • SAB
    Nicholas F. LaRusso, M.D.
    Liver disease 35+ yrs
R&D Advisory
  • David J. Pepperl, Ph.D.
    Pre-clinical, IND 20+ yrs
  • Chul Kim M.D., Ph.D.
    Clinical medicine, Oncology 25+ yrs
  • Kiyean Nam, Ph.D.
    Clinical development 20+ yrs
  • Yoon-Koo Kang,
    MD., Ph.D.
    Clinical Medicine, Oncology 30+yrs
Co-Researchers
  • Harmeet Malhi, M.B.B.S.
    Mayo Clinic,
    Liver disease 20+ yrs
  • Howard C. Hang, Ph. D.
    Scripps Research Institute,
    Bacteria Immunology 20+ yrs